Gerardiphar SRL
Gerardiphar reported total assets of 931,701 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of Gerardiphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -57 % Total assets -55 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Gerardiphar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −5,989 € | ||||
| Equity | 323,275 € | ||||
| Cash | 131,967 € | ||||
| EBITDA | 61,855 € | ||||
| Total assets | 931,701 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 25 Nov 2025
- Year ended 31 Dec 2023filed on 11 Jul 2024
- Year ended 31 Dec 2022filed on 30 Aug 2023
- Year ended 31 Dec 2021filed on 30 Sep 2022
Gerardiphar's financial analysis
- Solvency34.7%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Gerardiphar
Gerardiphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0867.474.364
- VAT number
- BE0867474364
- Peppol
- Registered · 0208:0867474364 · as of 11 Nov 2026
- Legal form
- SRL
- Incorporated
- 28 Sep 2004
- Registered office
- 8200 Bruges
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Gerardiphar (SRL) has been based in Bruges since 2004, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 5,989 € and equity of 323,275 €; its revenue is not published. Its solvency stands at 34.7%, below the median of its sector (44.2%).
Companies similar to Gerardiphar
Companies in the same business, of comparable size and area, outside its group.
- Yascare Retail sale of pharmaceutical products Uccle · balance sheet 34,424 €
- Pharma Poperinge Retail sale of pharmaceutical products Ghent · balance sheet 898,903 €
- Apotheek Vanneste TOM Retail sale of pharmaceutical products Kortrijk · balance sheet €1.04m
- AVA-Rose Retail sale of pharmaceutical products Jette · balance sheet 381,859 €
- Listien Retail sale of pharmaceutical products Lubbeek · balance sheet 961,817 €
- Pharmacie VAN Tomme Retail sale of pharmaceutical products Tournai · balance sheet 983,713 €
- Liwoma Retail sale of pharmaceutical products Kontich · balance sheet 289,010 €
- Farmafender Retail sale of pharmaceutical products Zedelgem · balance sheet 269,880 €
Frequently asked questions about Gerardiphar
What is the revenue of Gerardiphar?
Gerardiphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Gerardiphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0867474364 for Gerardiphar, if the company is VAT-registered. Its company number (CBE) is 0867.474.364.
Where is the registered office of Gerardiphar?
According to the CBE register, the registered office of Gerardiphar is in 8200 Bruges.
What is the equity of Gerardiphar?
At the close of the 2025 financial year, the equity of Gerardiphar amounts to 323,275 €, a solvency of 34.7% of total assets.
Who manages Gerardiphar?
The register lists 2 active mandates at Gerardiphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Gerardiphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →